Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Exclusion criteria

• ✕. Revised International Working Group (Cheson, 2007) Classification for systemic lymphoma or
• ✕. Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood
• ✕. or bone marrow mSWAT \> 0 or Sezary couny \>/= 1000 cells/ul
• ✕. Congenital long QT syndrome.
• ✕. QTc/QTf interval ≥ 480 milliseconds; unless secondary to pacemaker or bundle branch block.
• ✕. Myocardial infarction within 6 months. (Subjects with a history of myocardial infarction within the last 6 to12 months who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate.)
• ✕. Other significant ECG abnormalities including 2nd degree atrio- ventricular (AV) block (AV) block type II, 3rd degree AV block.
• ✕. Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see Appendix B). In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present.